Abstract:Abstract Objectives Flow cytometric immunophenotyping (FCI) is a fast and sensitive method for characterizing hematolymphoid neoplasms. It is not widely used in the workup of systemic mastocytosis (SM), in part because of the technical challenges and in part because the utility of FCI in assessing mast cells is not well understood. The objectives of this study were to assess the diagnostic utility of FCI in establishing a diagnosis of SM and distinguishing SM from nonneoplastic mast cells and to examine the immunophenotypic findings among SM subtypes. Methods We performed FCI on bone marrow samples suspicious for SM using a panel consisting of CD2, CD25, CD30, CD45, CD117, and HLA-DR. Results The cohort included 88 SM cases: 67 without an associated hematologic neoplasm (AHN) (PureSM) and 21 with an AHN (SM-AHN). We also assessed 40 normal/reactive controls. Overall, FCI was adequate for interpretation in 87 of 88 (99%) cases and detected at least 1 immunophenotypic aberrancy in 100% of SM cases. CD2, CD25, and CD30 were positive in 78%, 98%, and 90% of SM cases vs 0%, 13%, and 13% of cases with normal/reactive mast cells (P < .0001 for all). Two or 3 abnormalities were observed in 92% of SM cases but not in normal/reactive mast cells. Among SM cases, SM-AHN showed statistically significant less CD2 (38% vs 91%, P < .0001) and less co-expression of all 3 aberrant markers (CD2, CD25, and CD30 positive in 38% vs 86% of cases; P < .0001) than PureSM. Immunohistochemical analysis showed consistently weaker or focal expression of CD2, CD25, and CD30 than FCI, with CD2 and CD30 being falsely negative in 40% and 50% cases, respectively. A KIT D816V mutation was detected in 67% of PureSM cases and 76% of SM-AHN cases. Conclusions Flow cytometric immunophenotyping is a quick, sensitive, high-yield tool for evaluating the immunophenotype of mast cells. An abnormal FCI finding should prompt careful histologic evaluation and sensitive KIT D816V mutation testing to address the possibility of SM. CD2, CD25, and CD30 are important markers for the detection of immunophenotypic aberrancy of mast cells, and their frequencies of aberrancy differ across SM subtypes.

Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1

Systemic mastocytosis with an associated hematological neoplasm (acute myeloid leukaemia with RUNX1::RUNX1T1 fusion) – A case study

A Multicenter Retrospective Comparison Between Systemic Mastocytosis with T(8;21) AML and KIT Mutant T(8;21) AML.

Acute Myeloid Leukemia with T(8;21)(q22;q22.1)/runx1-Runx1t1 and KIT Exon 8 Mutation is Associated with Characteristic Mastocytosis and Dismal Outcomes

A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML

Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow

Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis

How I diagnose systemic mastocytosis

Systemic Mastocytosis Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: a Case Report

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

Prevalence and impact of the KIT M541L variant in patients with mastocytosis

Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity

T-cell immune profile in blood of systemic mastocytosis: Association with disease features

Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation

A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis

MASTering systemic mastocytosis: Lessons learned from a large patient cohort

Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation

SOHO State of the Art Update and Next Questions | Current and Emerging Therapies for Systemic Mastocytosis

Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis